



VGX Pharmaceuticals Announces Management Promotions

Blue Bell, PA – October 18, 2006 –

VGX Pharmaceuticals announced the promotion of Dr. Bryan B. J. Kim to Senior Director, Corporate Development and the promotion of Anthony Kim to Director, Investor Relations.

“Bryan has been providing invaluable service in all aspects of our business, especially with VGX International, which plays an important role in our strategy to become a global pharmaceutical company,” said Dr. J. Joseph Kim, a CEO and President. “This promotion recognizes the important role he has played in our Company’s growth and I am confident that he will continue to be a key part of the overall success of the Company.”

Dr. Kim joined the Company in 2005 as Director. In addition to his responsibilities with VGX, Dr. Kim is also a Clinical Assistant Professor at University of Pennsylvania, School of Dental Medicine where he has developed innovative clinical programs and directed important research projects granted by NIDH in microbiology and immunology. Dr. Kim holds a Bachelor of Arts degree in Economics and a Bachelor of Science degree in Biological Science, both from University of California at Irvine. He also holds a Doctor of Dental Medicine degree from the University of Pennsylvania.

Anthony Kim joined the Company in 2005 as Associate Director. He has been responsible for Investor Relations, addressing the needs of our diverse group of investors for both VGX Pharmaceuticals and VGX International. Mr. Kim has over 10 years of experience in the securities and banking industry. Prior to joining the Company he led a financial services company in which he assisted his clients in raising money from high net-worth individuals and financial institutions. Mr. Kim holds Bachelor's Degree in Economics from the University of Washington.

“Anthony has been instrumental in leading the Investor Relations activity at our Company and his contributions to our operation have been invaluable. I expect his role and contributions to our company to continue to grow,” said Dr. Kim.

Cautionary Factors That May Affect Future Results - Materials in this Press Release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on www.vgxp.com as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

About VGX Pharmaceuticals

VGX Pharmaceuticals is a leading biopharmaceutical company with strong product candidates for the treatment of infectious diseases including HIV and hepatitis C virus (HCV) as well as cancer and inflammatory diseases. The Company's clinical development programs include PICTOVIR™ for HIV infection and VGX-410C for chronic HCV infection, which are currently in Phase II clinical trials. In addition, a Phase I clinical trial will be initiated in 2007 for the Company's lead cancer drug compound, VGX-150 for the treatment of Melanoma. Moreover, VGX Pharmaceuticals' therapeutic platform is designed to advance a strong and continual pipeline of additional drug candidates into the clinic with VGX-100 for cancer therapy and VGX-1027 and VGX-750 for inflammatory diseases currently in development. The product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGX can be found at www.vgxp.com.

Company Contact:

Kevin W. Rassas

Senior Vice President

Tel. 267.440.4208

Fax 267.440.4242

E-mail: Rassas@vgxp.com

www.vgxp.com